Opinion|Videos|August 22, 2023
Available Treatment Options for Patients With Relapsed/Refractory (R/R) B-ALL
Author(s)Jae Park, MD
Dr Jae Park details the treatment options for relapsed/refractory B-cell acute lymphoblastic leukemia, including blinatumomab, inotuzumab ozogamicin, and CAR T-cell therapy, with the treatment choice dependent on patient factors like comorbidities, disease burden, and transplant status.
Advertisement
Episodes in this series
Advertisement
Related to this article
Paolo Tarantino, MD, PhD, discusses key data with ADCs in breast cancer that were presented at ASCO 2026.
The FDA has approved lutetium Lu 177 vipivotide tetraxetan plus an ARPI for PSMA-positive metastatic hormone-sensitive prostate cancer.
Andrew H. Ko, MD, discusses how TTFields works and data that supported the FDA approval of Optune Pax for patients with pancreatic cancer.
Shorter treatments of venetoclax plus azacitidine did not meet similarity criteria for longer treatments in Beat acute myeloid leukemia.
A Mayo Clinic study found that a new immunotherapy helped patients with aggressive bladder cancer keep their bladder instead of having it removed.
A supplemental new drug application for selinexor plus ruxolitinib for myelofibrosis in August 2026 under the accelerated approval pathway.
Selinexor maintenance failed to significantly improve PFS vs placebo in TP53 wild-type advanced or recurrent endometrial cancer in the phase 3 XPORT-EC-042 trial.
Sarcoma management demands coordinated, subtype-specific care and treatment sensitivities delivered by a dedicated multidisciplinary team.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Lutetium Lu 177 Vipivotide Tetraxetan for PSMA+ mHSPC
2
European Commission Approves First-Line Dato-DXd for Immunotherapy-Ineligible Metastatic TNBC
3
FDA CTGTAC Votes in Favor of RP1/Nivolumab Data in Advanced Melanoma
4
FDA sNDA Submission Is Planned for Selinexor Plus Ruxolitinib in Myelofibrosis
5